The deal will focus on the development of basic research including studies on pathogenesis and drug susceptibility of cancer by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research.
Both the entities have agreed to share information and hold regular discussions in order to collaborate and transition findings from basic research to clinical research and development activities, leveraging the strengths of the two parties.
National Cancer Center Research Institute director Hitoshi Nakagama said: "NCC is expecting a lot to be newly created by exchanging an agreement for the partnership with Takeda.
"By sharing bio-resources, including various types of cancer cell lines and animal models, biological and biochemical techniques for functional screenings, and huge amounts of clinical materials attached with detailed pathological and clinical information, further acceleration for development of Japan-oriented novel medicine and diagnostics is expected to be promptly achieved."
In order to deepen their cooperation, Takeda has participated in an NCC-led national academic-industrial collaboration genomic screening project ‘SCRUM-Japan’, which involves nation-wide medical institutions and pharma industry to collaborate to screen oncogene abnormalities.
Takeda Oncology Therapeutic Area Unit head Michael Vasconcelles said: "By leveraging NCC’s clinical research with Takeda’s technology infrastructure and tools for drug discovery, we hope that together we can have greater impact in a shorter amount of time to bring innovative treatments to the oncology community."